Detalhe da pesquisa
1.
Effect of upper gastrointestinal disease on the pharmacokinetics of oral semaglutide in subjects with type 2 diabetes.
Diabetes Obes Metab
; 24(4): 684-692, 2022 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-34957654
2.
MEDI0382, a GLP-1 and glucagon receptor dual agonist, in obese or overweight patients with type 2 diabetes: a randomised, controlled, double-blind, ascending dose and phase 2a study.
Lancet
; 391(10140): 2607-2618, 2018 06 30.
Artigo
em Inglês
| MEDLINE | ID: mdl-29945727
3.
Novel hepato-preferential basal insulin peglispro (BIL) does not differentially affect insulin sensitivity compared with insulin glargine in patients with type 1 and type 2 diabetes.
Diabetes Obes Metab
; 19(4): 482-488, 2017 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-27888561
4.
Selective Inhibition of 11beta-Hydroxysteroiddehydrogenase-1 with BI 187004 in Patients with Type 2 Diabetes and Overweight or Obesity: Safety, Pharmacokinetics, and Pharmacodynamics After Multiple Dosing Over 14 Days.
Exp Clin Endocrinol Diabetes
; 130(12): 773-782, 2022 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-36343645
5.
Pharmacokinetic and Glucodynamic Responses of Ultra Rapid Lispro vs Lispro Across a Clinically Relevant Range of Subcutaneous Doses in Healthy Subjects.
Clin Ther
; 42(9): 1762-1777.e4, 2020 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-32900535
6.
Efficacy, Safety, and Mechanistic Insights of Cotadutide, a Dual Receptor Glucagon-Like Peptide-1 and Glucagon Agonist.
J Clin Endocrinol Metab
; 105(3)2020 03 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-31608926